Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis A (inactivated) and hepatitis B (recombinant) vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Engerix-B + Havrix refers to the combination or co-administration of two distinct vaccines developed by GSK: Engerix-B, a recombinant hepatitis B vaccine, and Havrix, an inactivated hepatitis A vaccine. While often administered separately, they are also available as a fixed-dose combination product branded as Twinrix. The combination is indicated for active immunization against infections caused by the hepatitis A virus (HAV) and the hepatitis B virus (HBV) in susceptible individuals. The hepatitis A component consists of the HM175 strain of HAV, which is inactivated with formaldehyde and adsorbed onto aluminum hydroxide. The hepatitis B component contains purified surface antigen (HBsAg) produced by recombinant DNA technology in Saccharomyces cerevisiae (yeast) cells and adsorbed onto aluminum phosphate. By inducing the production of specific antibodies against both viruses, the vaccine provides long-term protection against hepatitis A and B, which are major causes of viral hepatitis worldwide.
- Brand names
- Twinrix
- Other names
- HepA-HepB vaccineHepatitis A and Hepatitis B vaccine
Beyond the preview
Go deeper on hepatitis A (inactivated) and hepatitis B (recombinant) vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis A (inactivated) and hepatitis B (recombinant) vaccine.